Anticoagulation and psychotropic medications

Current Psychiatry Reports

Volumn 12, Issue 3, 2010, Pages 265-271

  Bachawati, Maurice ^a  

^a GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Adverse events; Anticoagulants; Anticoagulation medication; Antiplatelet; Antipsychotics; Bleeding risk; Cardiovascular medications; Cytochrome P450 enzyme; Drug interactions; Gastrointestinal bleed; Hemorrhage; Heparin; Pharmacokinetics; Psychotropic; Side effect; SSRI; Thrombolytic; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; CITALOPRAM; DONEPEZIL; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HERBACEOUS AGENT; HYPNOTIC AGENT; ILOPERIDONE; MIRTAZAPINE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; NORTRIPTYLINE; PALIPERIDONE; PAROXETINE; PHENOTHIAZINE DERIVATIVE; PSYCHOTROPIC AGENT; RIVASTIGMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; UNINDEXED DRUG; WARFARIN; ZIPRASIDONE; FIBRINOLYTIC AGENT;

ANTICOAGULANT THERAPY; BLEEDING; DEPRESSION; DIET SUPPLEMENTATION; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG SAFETY; GASTROINTESTINAL HEMORRHAGE; HEMOPHILIA; HEMOSTASIS; HERBAL MEDICINE; HIGH RISK POPULATION; HUMAN; LOW DRUG DOSE; PRESCRIPTION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL BLEEDING; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; HEALTH STATUS; HEART INFARCTION; MENTAL DISEASE; THROMBOEMBOLISM;

ANTICOAGULANTS; DRUG INTERACTIONS; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HEALTH STATUS; HUMANS; MENTAL DISORDERS; MYOCARDIAL INFARCTION; PSYCHOTROPIC DRUGS; THROMBOEMBOLISM;

EID: 77955285508     PISSN: 15233812     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11920-010-0120-z     Document Type: Review

References (57)

1. Geerts WH, Pineo GF, Heit JA, et al.: Prevention of venous thromboembolism: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004, 126(3 Suppl):338S-400S.
2. Williams S, Wynn G, Cozza K, Sandson NB: Cardiovascular medications. Psychosomatics 2007, 48:537-547. In this recent review, the authors discuss relevant clinical interactions of all cardiovascular medications, including anticoagulants with psychotropics.
3. Malý R, Masopust J, Hosák L, Konupcíková K: Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients. Psychiatry Clin Neurosci 2008, 62:3-8.
4. von Känel R, Hepp U, Buddeberg C, et al.: Altered blood coagulation in patients with posttraumatic stress disorder. Psychosom Med 2006, 68:598-604.
5. Geiser F, Meier C, Wegener I, et al.: Association between anxiety and factors of coagulation and fibrinolysis. Psychother Psychosom 2008, 77:377-383.
6. Lee LV: Anticoagulants in coronary artery disease. Cardiol Clin 2008, 26:615-628.
7. Ovid Technologies: Drug Facts & Comparisons. New York, NY: Ovid Technologies; 2008.
8. Faulx MD, Francis GS: Adverse drug reactions in patients with cardiovascular disease. Curr Probl Cardiol 2008, 33:703-768. Faulx and Francis provide a panoramic view of adverse drug reactions with cardiovascular medications, including anticoagulants.
9. Gross PL, Weitz JI: New antithrombotic drugs. Clin Pharmacol Ther 2009, 86:139-146.
10. Harder S, Klinkhardt U: Thrombolytics: Drug interactions of clinical significance. Drug Saf 2000, 23:391-399.
11. Crone C, Dobbelstein C: Gastrointestinal disorders. In The American Psychiatric Publishing Textbook of Psychosomatic Medicine, edn 2. Edited by Levenson JL. Washington, DC: American Psychiatric Publishing; 2010 (in press).
12. Wessinger S, Kaplan M, Choi L, et al.: Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: A multicentre retrospective analysis. Aliment Pharmacol Ther 2006, 23:937-944.
13. Flanagan RJ, Dunk L: Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008, 23(Suppl 1):27-41. Flanagan and Dunk show in this recent review the various mechanisms of hematologic toxicity of drugs used in psychiatry.
14. Opatrny L, Delaney JA, Suissa S: Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: A new look. Br J Clin Pharmacol 2008, 66:76-81.
15. Schalekamp T, Klungel OH, Souverein PC, de Boer A: Increased bleeding risk with concurrent use of selective serotonin reuptake inhibitors and coumarins. Arch Intern Med 2008, 168:180-185.
16. Tata LJ, Fortun PJ, Hubbard RB, et al.: Does concurrent prescription of selective serotonin reuptake inhibitors and nonsteroidal anti-inflammatory drugs substantially increase the risk of upper gastrointestinal bleeding? Aliment Pharmacol Ther 2005, 22:175-181.
17. Vidal X, Ibánez L, Vendrell L, et al.; Spanish-Italian Collaborative Group for the Epidemiology of Gastrointestinal Bleeding: Risk of upper gastrointestinal bleeding and the degree of serotonin reuptake inhibition by antidepressants: A case-control study. Drug Saf 2008, 31:159-168.
18. de Abajo FJ, García-Rodríguez LA: Risk of upper gastrointestinal tract bleeding associated with selective serotonin reuptake inhibitors and venlafaxine therapy: Interaction with nonsteroidal anti-inflammatory drugs and effect of acid-suppressing agents. Arch Gen Psychiatry 2008, 65:795-803.
19. de Abajo FJ, Rodríguez LA, Montero D: Association between selective serotonin reuptake inhibitors and upper gastrointestinal bleeding: Population based case-control study. BMJ 1999, 319:1106-1109.
20. Kurdyak PA, Juurlink DN, Kopp A, et al.: Antidepressants, warfarin, and the risk of hemorrhage. J Clin Psychopharmacol 2005, 25:561-564.
21. Helin-Salmivaara A, Saarelainen S, Grönroos JM, et al.: Risk of upper gastrointestinal events with the use of various NSAIDs: A case-control study in a general population. Scand J Gastroenterol 2007, 42:923-932.
22. Yuan Y, Tsoi K, Hunt RH: Selective serotonin reuptake inhibitors and risk of upper GI bleeding: Confusion or confounding? Am J Med 2006, 119:719-727.
23. Weinrieb RM, Auriacombe M, Lynch KG, Lewis JD: Selective serotonin re-uptake inhibitors and the risk of bleeding. Expert Opin Drug Saf 2005, 4:337-344.
24. Kim DH, Daskalakis C, Whellan DJ, et al.: Safety of selective serotonin reuptake inhibitor in adults undergoing coronary artery bypass grafting. Am J Cardiol 2009, 103:1391-1395.
25. Small NL, Giamonna KA: Interaction between warfarin and trazodone. Ann Pharmacother 2000, 34:734-736.
26. Sayal KS, Duncan-McConnell DA, McConnell HW, Taylor DM: Psychotropic interactions with warfarin. Acta Psychiatr Scand 2000, 102:250-255.
27. Sansone RA, Sansone LA: Warfarin and antidepressants: Happiness without hemorrhaging. Psychiatry (Edgmont) 2009, 6:24-29. This concise and revelatory article provides recent updates on antidepressants' interactions with warfarin.
28. Strain JJ, Caliendo G, Alexis JD, et al.: Cardiac drug and psychotropic drug interactions: Significance and recommendations. Heart Dis 2001, 3:248-262.
29. Oyesanmi O, Kunkel EJ, Monti DA, Field HL: Hematologic side effects of psychotropics. Psychosomatics 1999, 40:414-421.
30. Mazzucco S, Cipriani A, Barbui C, Monaco S: Antipsychotic drugs and cerebrovascular events in elderly patients with dementia: A systematic review. Mini Rev Med Chem 2008, 8:776-783.
31. Hägg S, Jönsson AK, Spigset O: Risk of venous thromboembolism due to antipsychotic drug therapy. Expert Opin Drug Saf 2009, 8:537-547.
32. Stewart AJ, Manson LM, Dasani H, et al.: Acquired haemophilia in recipients of depot thioxanthenes. Haemophilia 2000, 6:709-712.
33. Huang YW, Saidi P, Philipp C: Acquired factor VIII inhibitors in non-haemophilic patients: Clinical experience of 15 cases. Haemophilia 2004, 10:713-721.
34. Meyer J: Drug-drug interactions with antipsychotics. CNS Spectr 2007, 12(12 Suppl 21):6-9.
35. Abilify [package insert]. New York: Bristol-Myers Squibb; 2002.
36. Citrome L: Iloperidone for schizophrenia: A review of the efficacy and safety profile for this newly commercialised secondgeneration antipsychotic. Int J Clin Pract 2009, 63:1237-1248.
37. Fanapt [package insert]. East Hanover, NJ: Novartis; 2009.
38. Saphris [package insert].Whitehouse Station,NJ: Merck&Co.; 2009.
39. Citrome L: Asenapine for schizophrenia and bipolar disorder: A review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract 2009, 63:1762-1784.
40. Perucca E: Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006, 61:246-255.
41. Díaz RA, Sancho J, Serratosa J: Antiepileptic drug interactions. Neurologist 2008, 14(6 Suppl 1):S55-S65. In this article, the authors reviewed the day-to-day important interactions of anticonvulsants in clinical practice.
42. Johannessen Landmark C, Patsalos PN: Drug interactions involving the new second- and third-generation antiepileptic drugs. Expert Rev Neurother 2010, 10:119-140.
43. Dolder C, Nelson M, McKinsey J: Use of non-benzodiazepine hypnotics in the elderly: Are all agents the same? CNS Drugs 2007, 21:389-405.
44. Cozza KL, Armstrong SC, Oesterheld JR, Cozza KL: Cytochrome P450s, UGTs, p-glycoproteins. In Concise Guide to Drug Interaction Principles for Medical Practice. Washington, DC: American Psychiatric Publishing; 2003:369.
45. Robertson P Jr, Hellriegel ET, Arora S, Nelson M: Effect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers. J Clin Pharmacol 2002, 42:205-214.
46. Darwish M, Kirby M, Robertson P Jr, Hellriegel ET: Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects. Clin Pharmacokinet 2008, 47:61-74.
47. Sauer JM, Long AJ, Ring B, et al.: Atomoxetine hydrochloride: Clinical drug-drug interaction prediction and outcome. J Pharmacol Exp Ther 2004, 308:410-418.
48. Aricept [package insert]. Teaneck, NJ: Eisai; 2002.
49. Tiseo PJ, Foley K, Friedhoff LT: The effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin. Br J Clin Pharmacol 1998, 46(Suppl 1):45-50.
50. Razadyne [package insert]. Titusville, NJ: Janssen Pharmaceutica; 2001.
51. Yao C, Raoufinia A, Gold M, et al.: Steady-state pharmacokinetics of galantamine are not affected by addition of memantine in healthy subjects. J Clin Pharmacol 2005, 45:519-528.
52. Jann MW, Shirley KL, Small GW: Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors. Clin Pharmacokinet 2002, 41:719-739.
53. Tavassoli N, Sommet A, Lapeyre-Mestre M, et al.: Drug interactions with cholinesterase inhibitors: An analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary). Drug Saf 2007, 30:1063-1071.
54. Namenda [package insert]. New York: Forest Laboratories; 2003.
55. Sinxadi P, Blockman M: Warfarin resistance. Cardiovasc J Afr 2008, 19:215-217.
56. Hu Z, Yang X, Ho PC, et al.: Herb-drug interactions: A literature review. Drugs 2005, 65:1239-1282.
57. Gillman PK: Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br J Pharmacol 2007, 151:737-748. This article presented new data on the pharmacology of tricyclic antidepressants and their various interactions.